menu
    • menu
    [{"orgOrder":0,"company":"Wacker Chemie AG","sponsor":"CureVac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CVnCoV","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wacker Chemie AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Wacker Chemie AG \/ Wacker","highestDevelopmentStatusID":"10","companyTruncated":"Wacker Chemie AG \/ Wacker"},{"orgOrder":0,"company":"Wacker Chemie AG","sponsor":"Caeregen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"CTR-107","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Wacker Chemie AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Wacker Chemie AG \/ Caeregen Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Wacker Chemie AG \/ Caeregen Therapeutics"},{"orgOrder":0,"company":"Wacker Chemie AG","sponsor":"Pantherna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"PAN004","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Wacker Chemie AG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Wacker Chemie AG \/ Pantherna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Wacker Chemie AG \/ Pantherna Therapeutics"},{"orgOrder":0,"company":"Wacker Chemie AG","sponsor":"MinervaX ApS","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"GBS-NN\/NN2","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Wacker Chemie AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Wacker Chemie AG \/ MinervaX ApS","highestDevelopmentStatusID":"14","companyTruncated":"Wacker Chemie AG \/ MinervaX ApS"}]

    Find Clinical Drug Pipeline Developments & Deals by Wacker Chemie AG

    Menu

    Wacker Chemie AG

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    EXCIPIENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Wacker Chemie AG

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Wacker Chemie AG

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GBS-NN/NN2

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : MinervaX ApS

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            MinervaX and Wacker Partner On Group B Strep Vaccine Manufacturing

                            Details : The collaboration aims to manufacture MinervaX's active protein ingredients of its GBS vaccine, GBS NN, a novel, prophylactic vaccine against Group B Streptococcus.

                            Brand Name : GBS-NN/NN2

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            September 17, 2024

                            Lead Product(s) : GBS-NN/NN2

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : MinervaX ApS

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Wacker Chemie AG

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Wacker Chemie AG

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PAN004

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : Pantherna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Wacker and Pantherna Enhance Collaboration in mRNA Biopharmaceutical Development

                            Details : Through the collaboration, company aims to focus on the clinical development of PAN004, which is being evaluated in the preclinical studies for the treatment of acute respiratory distress syndrome.

                            Brand Name : PAN004

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 07, 2024

                            Lead Product(s) : PAN004

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Pantherna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Wacker Chemie AG

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Wacker Chemie AG

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTR-107

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I/ Phase II

                            Sponsor : Caeregen Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Caeregen Therapeutics and Wacker Biotech Announce Collaboration Agreement to Produce the Regenerative Medicine...

                            Details : The collaboration aims for the development and production of Noregen (CTR-107), a novel regenerative therapeutic, for treating retinal-related vision loss. CTR-107 is the first program to obtain FDA Rare Pediatric Disease Designation for Familial Exudati...

                            Brand Name : Noregen

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 28, 2023

                            Lead Product(s) : CTR-107

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Caeregen Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Wacker Chemie AG

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Wacker Chemie AG

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CVnCoV

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : CureVac

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            CureVac and WACKER Sign Manufacturing Contract for CureVac’s COVID-19 Vaccine Candidate, CVnCoV

                            Details : Under the terms of the initial agreement, WACKER will ramp up GMP (Good Manufacturing Practice) production of the mRNA drug substance for CVnCoV at its biotech site in Amsterdam in the first half of 2021.

                            Brand Name : CVnCoV

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            November 23, 2020

                            Lead Product(s) : CVnCoV

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : CureVac

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth